PHATHOM PHARMACEUTICALS, INC. Receivables, Net, Current
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Receivables, Net, Current of $97.42 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2026-07-30
- 2026-06-30: Receivables, Net, Current $97.42M.
- 2026-03-31: Receivables, Net, Current $80.72M.
- 2025-12-31: Receivables, Net, Current $78.13M.
- 2025-09-30: Receivables, Net, Current $55.79M.
| Period end | Receivables, Net, Current |
|---|---|
| 2026-06-30 | $97.42M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $80.72M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $78.13M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $55.79M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $51.26M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $36.36M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $38.80M 10-K · filed 2026-02-26 |
| 2024-09-30 | $21.05M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $10.88M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $3.88M 10-Q/A · filed 2024-06-14 |
| 2023-12-31 | $1.64M 10-K · filed 2025-03-06 |
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |